336 related articles for article (PubMed ID: 18413806)
1. SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome.
Cao X; Clavijo C; Li X; Lin HH; Chen Y; Shih HM; Ann DK
Mol Cancer Ther; 2008 Apr; 7(4):923-34. PubMed ID: 18413806
[TBL] [Abstract][Full Text] [Related]
2. Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.
Maroui MA; Kheddache-Atmane S; El Asmi F; Dianoux L; Aubry M; Chelbi-Alix MK
PLoS One; 2012; 7(9):e44949. PubMed ID: 23028697
[TBL] [Abstract][Full Text] [Related]
3. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
[TBL] [Abstract][Full Text] [Related]
4. SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.
Fasci D; Anania VG; Lill JR; Salvesen GS
Sci Signal; 2015 Jun; 8(380):ra56. PubMed ID: 26060329
[TBL] [Abstract][Full Text] [Related]
5. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
[TBL] [Abstract][Full Text] [Related]
6. Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts.
Xu WX; Liu SZ; Wu D; Qiao GF; Yan J
Cell Physiol Biochem; 2015; 37(4):1581-91. PubMed ID: 26517826
[TBL] [Abstract][Full Text] [Related]
7. The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.
Rabellino A; Carter B; Konstantinidou G; Wu SY; Rimessi A; Byers LA; Heymach JV; Girard L; Chiang CM; Teruya-Feldstein J; Scaglioni PP
Cancer Res; 2012 May; 72(9):2275-84. PubMed ID: 22406621
[TBL] [Abstract][Full Text] [Related]
8. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
9. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
10. Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies.
Geoffroy MC; Jaffray EG; Walker KJ; Hay RT
Mol Biol Cell; 2010 Dec; 21(23):4227-39. PubMed ID: 20943951
[TBL] [Abstract][Full Text] [Related]
11. Human Regulatory Protein Ki-1/57 Is a Target of SUMOylation and Affects PML Nuclear Body Formation.
Saito Â; Souza EE; Costa FC; Meirelles GV; Gonçalves KA; Santos MT; Bressan GC; McComb ME; Costello CE; Whelan SA; Kobarg J
J Proteome Res; 2017 Sep; 16(9):3147-3157. PubMed ID: 28695742
[TBL] [Abstract][Full Text] [Related]
12. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H
J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
14. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
[TBL] [Abstract][Full Text] [Related]
15. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress-induced assembly of PML nuclear bodies controls sumoylation of partner proteins.
Sahin U; Ferhi O; Jeanne M; Benhenda S; Berthier C; Jollivet F; Niwa-Kawakita M; Faklaris O; Setterblad N; de Thé H; Lallemand-Breitenbach V
J Cell Biol; 2014 Mar; 204(6):931-45. PubMed ID: 24637324
[TBL] [Abstract][Full Text] [Related]
17. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation.
Gao C; Ho CC; Reineke E; Lam M; Cheng X; Stanya KJ; Liu Y; Chakraborty S; Shih HM; Kao HY
Mol Cell Biol; 2008 Sep; 28(18):5658-67. PubMed ID: 18625722
[TBL] [Abstract][Full Text] [Related]
19. ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation.
Dassouki Z; Sahin U; El Hajj H; Jollivet F; Kfoury Y; Lallemand-Breitenbach V; Hermine O; de Thé H; Bazarbachi A
Blood; 2015 Jan; 125(3):474-82. PubMed ID: 25395419
[TBL] [Abstract][Full Text] [Related]
20. ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator.
Karvonen U; Jääskeläinen T; Rytinki M; Kaikkonen S; Palvimo JJ
J Mol Biol; 2008 Oct; 382(3):585-600. PubMed ID: 18656483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]